Press Release: Cutting-edge deep learning solutions that work with radiologists to improve breast cancer detection to be launched in Qatar

Kheiron Medical Technologies partners with Medtech Corporation to bring AI breast screening solution Mia® to Qatar healthcare community

-Mia is the first and only AI-enabled independent reader for breast cancer screening to be commercially available in the Qatar

Doha – Qatar, 25 July 2021 – Mia®, a deep learning artificial intelligence (AI) solution that works with radiologists to improve breast cancer detection, avoid unnecessary biopsies and ultimately improve the patient experience for all women is being launched in Qatar. 

UK-based Kheiron Medical Technologies has signed an agreement with Medtech Corporation, one of Qatar’s leading suppliers of medical and laboratory equipment, to bring its Mia solution to the Qatar market. With patented AI technology developed on more than three million breast images, Mia (Mammography Intelligent Assessment) is designed to support breast radiologists in making the critical decision to recall women for further testing based on their mammography screening. 

Mia is the first solution of its kind to receive the CE (European regulatory clearance) mark for use as an AI-enabled independent reader for the detection of breast cancer. Through rigorous clinical studies and testing, Mia has learnt to read mammograms to the same level of detail as a consulting radiologist. 

In double-reading mammography workflows where scans are reviewed by two radiologists, Mia can be deployed independently alongside a single human reader. This delivers the quality improvements needed to ensure the sustainability of breast screening services and frees up clinicians to spend more time with patients. Mia can also be deployed as a concurrent reader or in double reader triage.

Her Majesty’s Trade Commissioner for the Middle East, Simon Penney, added: “I am delighted that Kheiron Medical Technologies is bringing their breakthrough AI platform for breast screening, Mia, to the Gulf region, and that the UK’s Department for International Trade played a role in making this happen.  Kheiron’s technology brings pioneering artificial intelligence to the frontline, freeing up clinicians’ time and helping to save lives.”

Speaking at a signing ceremony between Kheiron and Medtech Corporation, Alex Hamlow, Kheiron’s Chief Commercial Officer, said; “Our mission at Kheiron is to support breast screening professionals in the fight against breast cancer with proven and effective AI-enabled tools. We’re excited that Mia is the first AI independent reader solution available for use within the breast screening community in Qatar. Based on its performance in the UK and Europe, Mia represents a major breakthrough in helping radiologists to dramatically improve breast cancer detection and patient outcomes. 

“According to the WHO’s International Agency for Research on Cancer, breast cancer was the most prevalent of all cancers detected in Qatar in 2020, accounting for 37.5% of all new cancer cases detected in women. I’m excited that Mia can help both radiologists and the women they care for,” Mr Hamlow continued.

“We are looking forward to bringing Kheiron’s Mia solution to Qatar’s breast screening community,” comments Dr. Hassan Kunhi, Chief Executive Officer for Medtech.  “Like Kheiron, we are driven by a desire to achieve the highest quality in everything we do. Mia has tremendous potential to improve radiologist productivity and empower breast screening professionals to detect potential malignancies more accurately and quickly. This means that Mia ultimately will help save more lives in the fight against breast cancer.”

Mia’s effectiveness has been proven in one of the most ambitious clinical studies in radiology AI to date and tested across multiple demographics and mammography devices.  It was one of the recipients of the UK Government’s first AI in Health and Care Awards through which Mia is undergoing multiple deployments and clinical studies across 15 sites in the UK as a benchmark for how to integrate new, cutting edge technologies into the NHS safely and effectively. Kheiron and AI Advance are currently working with an Australian breast-screening provider to establish the protocols for a forthcoming clinical trial, details of which will soon be announced.

Mia will be available to the UAE, Qatar and Oman markets pending local requirements.


About Kheiron Medical Technologies

Founded in 2016 by Peter Kecskemethy and Tobias Rijken, Kheiron Medical Technologies is an applied science company focused on supporting cancer diagnostics with machine learning that works with radiologists so that every patient has a better fighting chance. Its initial focus is improving the outcomes for the more than two million women diagnosed globally every year with breast cancer.  Operating in the United Kingdom, United States, and Europe, Kheiron is an international, multi-disciplinary team of senior clinicians, industry experts, engineers and machine learning scientists.


About Medtech Corporation     

As one of Qatar’s leading suppliers of medical and laboratory equipment, Medtech provides the world’s best medical and laboratory equipment to government and private institutions across Qatar and the Middle East. Medtech’s customer-centric approach has enabled them to grow steadily over the past 40 years, and they continue to deliver on their mission of bringing the best in medical and diagnostic technology to Qatar’s leading hospitals and healthcare centers.


For more information, please contact:

Gina Mehmert

VP, Global Commercial Marketing

Kheiron Medical Technologies

[email protected]

Latest articles

PR

11th May 2022

Kheiron Forms US Breast Medical Advisory Board; Appoints Three Leaders With Deep Track Record Advocating For Women’s Health

Dr. Wendy DeMartini, Dr. Elizabeth Morris, and Dr. Amy Patel are trailblazers at the forefront of introducing innovative breast imaging technologies into clinical practice (London ...

Read more
Latest articles

PR

4th May 2022

InHealth signs up to AI Award with Kheiron

InHealth, who provide services for North and East Devon NHS Breast Screening, has entered into the research agreement to work with Kheiron Medical Technologies as part of the AI in...

Read more
Latest articles

PR

9th March 2022

Kheiron included in Fast Company’s Most Innovative Companies 2022 list

This AI cancer diagnostics company joins the ranks of Canva, Microsoft, SpaceX, and other winning companies that are changing lives for the better (London –  March 9, 20...

Read more
Latest articles

PR

30th November 2021

Dr Ben Glocker Joins Kheiron

As Head of Machine Learning Research, Glocker will help make sure that Kheiron’s algorithms generalize and can help patients, regardless of their ethnic background or where they ...

Read more
Latest articles

PR

29th November 2021

Kheiron Introduces RSViP to U.S.

AI-Enabled Scheduling Tool That Focuses Attention on Women Who Need Breast Screening the Most Nov. 29, 2021 – As many as 3.9 million women in the U.S. missed their routine ma...

Read more
Latest articles

PR

29th November 2021

Stanford University Partners with Kheiron

Collaboration leverages Stanford’s clinical expertise and Kheiron’s machine learning capabilities to assist radiologists in more effectively staging and monitoring treatment re...

Read more
Latest articles

PR

29th November 2021

Kheiron Introduces Mia IQ to U.S.

Award-Winning AI Solutions Developer Launches Image Quality Assurance Tool to Support Radiographers and Radiologists in Breast Screening Process Nov. 29, 2021 – To aid breast...

Read more
Latest articles

PR

27th October 2021

Royal Free London NHS Foundation Trust signs up to AI Award with Kheiron

“The study will provide evidence to help assess whether the use of AI in this instance could be a viable option,” said Dr William Teh, clinical lead with Royal Free London NHS ...

Read more
Latest articles

PR

27th October 2021

Kheiron, Gateshead Health Foundation NHS Trust Enter Research Agreement

Partnership marks significant step in the journey to build evidence base to demonstrate effectiveness and safety of AI in NHS breast cancer screening LONDON, 26 October 2021–&nbs...

Read more
1 2 3 7